Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12879-016-1823-5 http://scihub22266oqcxt.onion/10.1186/s12879-016-1823-5 C5025565!5025565!27633969     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMC+Infect+Dis 2016 ; 16 (ä): ä Nephropedia Template TP {{tp|p=27633969|t=2016. The efficacy of thymosin ?1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials |pdf=|usr=}}{{27633969}} gab.com Text The efficacy of thymosin 1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials JO: BMC Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=27633969 #FOAvip Background: Thymosin ?1 (T?1) as immunomodulatory treatment is supposed to be beneficial for the sepsis patients by regulating T cell subsets and inflammatory mediators. However, limited by the small sample size and the poor study design, the persuasive power of the single clinical studies is weak. This meta-analysis aimed to investigate the impact of T?1 on the sepsis patients. Methods: We searched for the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, VIP, CNKI, WANFANG, Igaku Chuo Zasshi (ICHUSHI) and Korean literature databases reporting the effects of T?1 on outcomes in sepsis patients. Results: Among 444 related articles, 19 randomized controlled trials (RCTs) met our inclusion criteria. Mortality events were reported in 10 RCTs included 530 patients, and the meta-analysis showed significant decrease in T?1 group compared with control group (RR 0.59, 95 % CI 0.45 to 0.77, p?=?0.0001). The subgroup analysis showed no difference between the two dosages (RR 0.59, 95 % CI 0.43 to 0.81; RR 0.59, 95 % CI 0.35 to 0.98, respectively). In 9 RCTs, with a total of 489 patients, T?1 administered once per day decrease APACHE II score significantly (SMD ?0.80, 95 % CI ?1.14 to ?0.47, p?<?0.0001) while T?1 twice per day showed no effect (SMD 0.30, 95 % CI-0.10 to 0.70, p?=?0.14). However, the length of ICU stay, the incidence of multiple organ failure (MOF) and duration of mechanical ventilation were not significantly affected by T?1 treatment (SMD ?0.52, 95 % CI ?1.06 to 0.11, p?=?0.06; SMD ?0.49, 95 % CI ?1.09 to 0.11, p?=?0.11; SMD ?0.37, 95 % CI ?0.90 to 0.17, p?=?0.17, respectively). As to the immunological indicators, the level of HLA-DR were increased by T?1 (SMD 1.23, 95 % CI 0.28 to 2.18, p?=?0.01) according to the pooled analysis of 8 studies involving 721 patients. Lymphocyte subsets CD3, CD4 and cytokines IL-6, IL-10 and TNF-? were also beneficially affected by T?1 treatment. Conclusions: T?1 may be beneficial to sepsis patients in reducing mortality and modulating inflammation reactions. However, the quality of evidence supporting the effectiveness is low considering the small sample sizes and inadequate adherence to standardized reporting guidelines for RCTs among the included studies. Twit Text FOAVip The efficacy of thymosin 1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials ????BMC Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=27633969 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27633969 #FOAvip English Wikipedia <ref>{{Cite pmid|27633969}}</ref> The efficacy of thymosin ?1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials #MMPMID27633969 Liu F; Wang HM; Wang T; Zhang YM; Zhu X BMC Infect Dis 2016[]; 16 (ä): ä PMID27633969show ga Background: Thymosin ?1 (T?1) as immunomodulatory treatment is supposed to be beneficial for the sepsis patients by regulating T cell subsets and inflammatory mediators. However, limited by the small sample size and the poor study design, the persuasive power of the single clinical studies is weak. This meta-analysis aimed to investigate the impact of T?1 on the sepsis patients. Methods: We searched for the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, VIP, CNKI, WANFANG, Igaku Chuo Zasshi (ICHUSHI) and Korean literature databases reporting the effects of T?1 on outcomes in sepsis patients. Results: Among 444 related articles, 19 randomized controlled trials (RCTs) met our inclusion criteria. Mortality events were reported in 10 RCTs included 530 patients, and the meta-analysis showed significant decrease in T?1 group compared with control group (RR 0.59, 95 % CI 0.45 to 0.77, p?=?0.0001). The subgroup analysis showed no difference between the two dosages (RR 0.59, 95 % CI 0.43 to 0.81; RR 0.59, 95 % CI 0.35 to 0.98, respectively). In 9 RCTs, with a total of 489 patients, T?1 administered once per day decrease APACHE II score significantly (SMD ?0.80, 95 % CI ?1.14 to ?0.47, p? äThe efficacy of thymosin ?1 as immunomodulatory treatment for sepsis: (epmc).pdf DeepDyve Pubget Overpricing